Top Markets
Coin of the day
Bristol-Myers Squibb Company Bristol-Myers Squibb Company

Bristol-Myers Squibb Company

BMY
株式のランク #149
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and... Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
株価
$59.43
時価総額
$121.03B
変化(1日)
0.83%
変化(1年)
0.90%
US
取引 Bristol-Myers Squibb Company (BMY)

カテゴリー

Bristol-Myers Squibb Company(BMY)の営業利益率
March 2026 時点の営業利益率 TTM: 26.34%
Bristol-Myers Squibb Company の最新の財務報告と株価によると、現在の営業利益率(TTM)は 26.34% です。2024 年末時点では 20.00% でした。
Bristol-Myers Squibb Company の営業利益率の履歴(2000 から 2026)
各年末の営業利益率
営業利益率 変化
2026 (TTM) 26.34% 0.00%
2025 26.34% 31.70%
2024 20.00% 6.27%
2023 18.82% -6.27%
2022 20.08% -2.38%
2021 20.57% 94.79%
2020 10.56% -57.13%
2019 24.63% -13.09%
2018 28.34% 12.37%
2017 25.22% -5.40%
2016 26.66% 12.11%
2015 23.78% 20.47%
2014 19.74% 3.35%
2013 19.10% -21.14%
2012 24.22% -23.79%
2011 31.78% 0.92%
2010 31.49% 17.32%
2009 26.84% 13.39%
2008 23.67% 21.57%
2007 19.47% 32.00%
2006 14.75% -31.33%
2005 21.48% -11.42%
2004 24.25% 2.71%
2003 23.61% 4.33%
2002 22.63% -14.80%
2001 26.56% -19.17%
2000 32.86% 0.00%
同業他社の営業利益率
企業 営業利益率 営業利益率の差
45.56% -98.27%
US
23.28% -99.12%
GB
27.17% -98.97%
US
26.72% -98.99%
US
31.24% -98.81%
CH
企業の営業利益率とは?
営業利益率は、企業の収益性を評価するための重要な指標です。高い営業利益率は一般的に良いとされており、企業が製品やサービスをその生産コストよりもはるかに高く販売できていることを示します。営業利益率は、企業の利益を売上高で割ることで計算されます。